Find trials
Consejos para buscar

Exploring the Role of B-cell Activating Factor Receptor (BAFFR)-based Chimeric Antigen Receptor T-cell (CAR T) in BAFFR-expressing B-cell Hematologic Malignancies and Autoimmune Rheumatologic Disorders

Overview

Información sobre este estudio

The purposes of this study are to explore the therapeutic efficacy of BAFFR-CAR T cells in BAFFR-expressing B-cell hematologic malignancies including large B-cell, mantle cell and follicular lymphoma, chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-cell ALL) using primary tumor and/or patient derived xenograft models, and to explore the therapeutic efficacy of BAFFR-CAR T cells in autoimmune rheumatologic diseases including  systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models.

 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria - Patient Cohort:

  • Individuals (male or female) diagnosed with B-cell lymphomas, CLL or B-cell ALL, and undergoing a blood draw, scheduled biopsy or surgical procedure for the purpose of collection of the tissue (such as lymph nodes); OR
  • Individuals (male or female) diagnosed with SLE, RA, ANCA-associated vasculitis, and undergoing a blood draw, scheduled biopsy, or surgical procedure for the purpose of collection of tissue including but not limited to kidney and/or skin biopsy.
  • ≥ 18 years of age.
  • Willing to sign informed consent.
  • Willing to provide clinical data and blood and/or tissue.

Exclusion Criteria - Patient Cohort:

  • Inability to understand and sign informed consent.
  • Inability to confirm diagnosis of a hematologic malignancy or a rheumatologic disorder from medical records. 
  • Pregnant patients. Negative pregnancy will be confirmed by verbal confirmation or as is noted in the medical record.

Eligibility last updated 9/23/21. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Mohamed Kharfan Dabaja, M.D., M.B.A.

Abierto para la inscripción

Contact information:

Mohamed Kharfan Dabaja M.D., M.B.A.

KharfanDabaja.Mohamed@mayo.edu

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20513089

Mayo Clinic Footer